News and Press Releases
Enterprise Therapeutics achieves primary efficacy outcome in Phase 2 clinical trial for cystic fibrosis with novel inhaled ENaC blocker ETD001
First investigational inhaled ENaC blocker to deliver clinically relevant and statistically significant change in lung function compared to placebo Inhaled therapeutic designed to treat the 10% of people with cystic...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: May 12, 2026
Sussex Innovation Centre, University of Sussex, Science Park Square, Falmer, Brighton, BN1 9SB, UK
PACE launches its third funding round today, supporting innovative projects that tackle resistant bacterial infections posing the greatest threat to global health
1 October 2025 -- Alderley Park, UK -- To stay ahead of the escalating antibiotic resistance crisis, we need bold thinking and transformative innovation. According to the World Health Organization...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: October 1, 2025
Vertex Announces UK MHRA Approval of ALYFTREK (Deutivacaftor/Tezacaftor/Vanzacaftor), a Once-Daily Next-in-Class CFTR Modulatorfor the Treatment of Cystic Fibrosis
Deutivacaftor/tezacaftor/vanzacaftor approved for people with cystic fibrosis 6 years and older with at least one responsive mutation in the CFTR gene, including additional mutations not previously approved with other CFTR...
Category: Drug Discovery, Other, Pharmaceutical
Posted: March 7, 2025
Boehringer Ingelheim and partners start clinical development of a first-in-class, inhaled gene therapy for people with cystic fibrosis
Ingelheim, Germany – Boehringer Ingelheim, IP Group, the UK Respiratory Gene Therapy Consortium (GTC)1 and OXB,1 today announce the start of LENTICLAIRTM 1, a Phase I/II trial of BI 3720931,...
Category: Biotechnology
Posted: February 24, 2025
Glox Therapeutics Awarded Share of £3M Collaborative Discovery Programme Funding from Cystic Fibrosis Antimicrobial Resistance Syndicate
£500K grant to advance discovery and development of effective precision antibiotics targeting antimicrobial-resistant lung infections in people with cystic fibrosis Programme delivered by CF AMR Syndicate offers cross-sector collaboration and...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 21, 2025
11 The Square University Of Glasgow University Avenue Glasgow G12 8QQ
ERS Genomics and Medicines Discovery Catapult sign CRISPR/Cas9 license agreement
Partnership provides Medicines Discovery Catapult access to CRISPR gene editing technology across a broad range of drug discovery applications 04 September 2024 – Dublin, Ireland, and Cheshire, UK – ERS...
Category: BioManufacturing
Posted: September 9, 2024
Destiny Pharma initiates research to explore XF drug potential for CF
Study to investigate the potential of XF-73 to treat MRSA infection in people with cystic fibrosis 14 August 2024 -- Brighton, UK -- Destiny Pharma, a clinical stage biotechnology company...
Category: Biotechnology, Clinical Trials, Pharmaceutical
Posted: August 14, 2024
Destiny Pharma plc, Sussex Innovation Centre, Science Park Square, Brighton, BN1 9SB UK
Enterprise Therapeutics appoints Dr Renu Gupta as chief medical officer and Dr Janet Hammond as non-executive director
Appointments bring additional respiratory and late clinical-stage drug development experience as company commences Phase 2a clinical trial of its lead asset 17 June 2024, Brighton, UK -: Enterprise Therapeutics Ltd...
Category: Biotechnology, Pharmaceutical
Posted: June 17, 2024
Sussex Innovation Centre, University of Sussex, Science Park Square, Falmer, Brighton, BN1 9SB, UK
Enterprise Therapeutics publishes preclinical profile of ETD001, a novel inhaled ENaC blocker
Low doses of ETD001 demonstrate exceptionally long duration of action in sheep model of airway mucus clearance Report in Journal of Cystic Fibrosis discloses best-in-class profile of ETD001 ETD001 scheduled...
Category: Biotechnology, Clinical Trials, Drug Delivery, Drug Discovery, Pharmaceutical
Posted: June 12, 2024
Sussex Innovation Centre, University of Sussex, Science Park Square, Falmer, Brighton, BN1 9SB, UK
New £30m Initiative to Address Global Threat by Accelerating the Pace of Antimicrobial Innovation
Pioneering partnership to drive development of new tests and treatments to tackle deadly antimicrobial resistance, which could otherwise kill 10 million a year by 2050 19 October 2023 -- Swindon,...
Category: Other
Posted: October 19, 2023
